Search

Your search keyword '"Vaisman, Fernanda"' showing total 237 results
Start Over Author "Vaisman, Fernanda"
237 results on '"Vaisman, Fernanda"'

6. Clinical decision support analysis of a microRNA-based thyroid molecular classifier: A real-world, prospective and multicentre validation study

Author

Santos, Marcos Tadeu, Rodrigues, Bruna Moretto, Shizukuda, Satye, Oliveira, Andrei Félix, Oliveira, Miriane, Figueiredo, David Livingstone Alves, Melo, Giulianno Molina, Silva, Rubens Adão, Fainstein, Claudio, dos Reis, Gerson Felisbino, Corbo, Rossana, Ramos, Helton Estrela, Camacho, Cléber Pinto, Vaisman, Fernanda, and Vaisman, Mário

Published
2022
Full Text
View/download PDF

10. Restarting Elective Bariatric and Metabolic Surgery Under a Security Protocol During the COVID-19 Pandemic—a Prospective Observational Cohort Study

Author

Balieiro, Marcio P. M., da Silva, Michel M., Coelho, Antônio C. J., de Barros, Fernando, Saboya, Carlos, Ferraz, Leonardo R., Vieira, Mauricio E. G., Benevenuto, Dyego Sá, de Oliveira e Silva, Luiz G., Lucas, Marcio, Valente, Fernando, Viegas, Fabio, Kaddoum, Fernando J., El-Kadre, Luciana J., and Vaisman, Fernanda

Published
2021
Full Text
View/download PDF

11. External beam radiation therapy for recurrent or residual thyroid cancer: What is the best treatment time and the best candidate for long‐term local disease control?

Author

Cavalcante, Lara Bessa Campelo Pinheiro, primary, Treistman, Natalia, additional, Gonzalez, Fabiola Maria Teresa Torres, additional, Fernandes, Pollyanna Iemini Weyll, additional, Alves Junior, Paulo Alonso Garcia, additional, Andrade, Fernanda Accioly, additional, Ferreira, Elisa Napolitano, additional, Brito, Tarcisio Fontenele De, additional, Pane, Attilio, additional, Corbo, Rossana, additional, Erlich, Felipe, additional, Bulzico, Daniel Alves, additional, and Vaisman, Fernanda, additional

Published
2024
Full Text
View/download PDF

12. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study

Author

Capdevila, Jaume, primary, Krajewska, Jolanta, additional, Hernando, Jorge, additional, Robinson, Bruce, additional, Sherman, Steven I., additional, Jarzab, Barbara, additional, Lin, Chia-Chi, additional, Vaisman, Fernanda, additional, Hoff, Ana O., additional, Hitre, Erika, additional, Bowles, Daniel W., additional, Williamson, Denise, additional, Levytskyy, Roman, additional, Oliver, Jennifer, additional, Keam, Bhumsuk, additional, and Brose, Marcia S., additional

Published
2024
Full Text
View/download PDF

13. An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer

Author

Nixon, Iain J, Wang, Laura Y, Migliacci, Jocelyn C, Eskander, Antoine, Campbell, Michael J, Aniss, Ahmad, Morris, Lilah, Vaisman, Fernanda, Corbo, Rossana, Momesso, Denise, Vaisman, Mario, Carvalho, Andre, Learoyd, Diana, Leslie, William D, Nason, Richard W, Kuk, Deborah, Wreesmann, Volkert, Morris, Luc, Palmer, Frank L, Ganly, Ian, Patel, Snehal G, Singh, Bhuvanesh, Tuttle, R Michael, Shaha, Ashok R, Gönen, Mithat, Pathak, K Alok, Shen, Wen T, Sywak, Mark, Kowalski, Luis, Freeman, Jeremy, Perrier, Nancy, and Shah, Jatin P

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Age Factors, Brazil, Cell Differentiation, Decision Support Techniques, Disease-Free Survival, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Staging, New South Wales, North America, Predictive Value of Tests, Reproducibility of Results, Retrospective Studies, Risk Assessment, Risk Factors, Thyroid Neoplasms, Treatment Outcome, Clinical Sciences, Endocrinology & Metabolism, Clinical sciences
Abstract

BackgroundAge is a critical factor in outcome for patients with well-differentiated thyroid cancer. Currently, age 45 years is used as a cutoff in staging, although there is increasing evidence to suggest this may be too low. The aim of this study was to assess the potential for changing the cut point for the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system from 45 years to 55 years based on a combined international patient cohort supplied by individual institutions.MethodsA total of 9484 patients were included from 10 institutions. Tumor (T), nodes (N), and metastasis (M) data and age were provided for each patient. The group was stratified by AJCC/UICC stage using age 45 years and age 55 years as cutoffs. The Kaplan-Meier method was used to calculate outcomes for disease-specific survival (DSS). Concordance probability estimates (CPE) were calculated to compare the degree of concordance for each model.ResultsUsing age 45 years as a cutoff, 10-year DSS rates for stage I-IV were 99.7%, 97.3%, 96.6%, and 76.3%, respectively. Using age 55 years as a cutoff, 10-year DSS rates for stage I-IV were 99.5%, 94.7%, 94.1%, and 67.6%, respectively. The change resulted in 12% of patients being downstaged, and the downstaged group had a 10-year DSS of 97.6%. The change resulted in an increase in CPE from 0.90 to 0.92.ConclusionsA change in the cutoff age in the current AJCC/UICC staging system from 45 years to 55 years would lead to a downstaging of 12% of patients, and would improve the statistical validity of the model. Such a change would be clinically relevant for thousands of patients worldwide by preventing overstaging of patients with low-risk disease while providing a more realistic estimate of prognosis for those who remain high risk.

Published
2016

14. Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?

Author

Ganly, Ian, Nixon, Iain J, Wang, Laura Y, Palmer, Frank L, Migliacci, Jocelyn C, Aniss, Ahmad, Sywak, Mark, Eskander, Antoine E, Freeman, Jeremy L, Campbell, Michael J, Shen, Wen T, Vaisman, Fernanda, Momesso, Denise, Corbo, Rossana, Vaisman, Mario, Shaha, Ashok, Tuttle, R Michael, Shah, Jatin P, and Patel, Snehal G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Patient Safety, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Adenocarcinoma, Adult, Age Factors, Age of Onset, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Neoplasm Staging, Nomograms, Prognosis, Survival Rate, Thyroid Neoplasms, Endocrinology & Metabolism, Clinical sciences
Abstract

BackgroundIn most staging systems, 45 years of age is used to differentiate low risk thyroid cancer from high risk thyroid cancer. However, recent studies have questioned both the precise 45 year age point and the concept of using a binary cut off as accurate predictors of disease specific mortality.MethodsA cohort of 3664 thyroid cancer patients that received surgery and adjuvant treatment at Memorial Sloan Kettering Cancer Center (MSKCC) from the years 1985 to 2010 were analyzed to determine the significance of age at diagnosis as a categorical variable at a variety of age cutoffs (5 year intervals between 30 and 70 years of age). The unadjusted and adjusted hazard ratio for the association between disease-specific survival and age was determined using a Cox proportional hazards model adjusted for other predictive variables sex, histology, and pathological T, N, and M status. Furthermore, predictive nomograms of disease-specific mortality were created and validated on an external dataset of 4551 patients to evaluate the impact of age at diagnosis as both a categorical and continuous variable.ResultsIn the MSKCC cohort, with a median follow-up time of 54 months (range 1-332), there were 59 deaths from thyroid cancer with a 10 year disease-specific survival of 96%. Adjusted hazard ratios for all age cutoffs from age 30 to age 70 years were significant. There was no specific cutoff age which risk stratifies patients with differentiated thyroid cancer (DTC). Categorizing age into five strata (70 years) showed a 37-fold increase in hazard ratio from age 70 years. A predictive nomogram using age as a continuous variable with other predictive variables had a high concordance index of 96%. Validation on the external cohort had a concordance index of 73%.ConclusionsMortality from DTC increases progressively with advancing age. There is no specific cutoff age which risk stratifies patients with DTC. A predictive nomogram using age as a continuous variable may be a more appropriate tool for stratifying patients with DTC and for predicting outcome.

Published
2015

21. TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma

Author

Penna, Gustavo C., Pestana, Ana, Cameselle, José Manuel, Momesso, Denise, de Andrade, Fernanda Accioly, Vidal, Ana Paula Aguiar, Araujo Junior, Mario Lucio, Melo, Miguel, Fernandes, Priscila Valverde, Corbo, Rossana, Vaisman, Mario, Sobrinho-Simões, Manuel, Soares, Paula, and Vaisman, Fernanda

Published
2018
Full Text
View/download PDF

22. Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)

Author

Ho, Alan L., Dedecjus, Marek, Wirth, Lori J., Tuttle, R. Michael, Inabnet, William B., Tennvall, Jan, Vaisman, Fernanda, Bastholt, Lars, Gianoukakis, Andrew G., Rodien, Patrice, Paschke, Ralf, Elisei, Rossella, Viola, David, So, Karen, Carroll, Danielle, Hovey, Tina, Thakre, Bhavana, and Fagin, James A.

Subjects
Iodine Radioisotopes, Cancer Research, Clinical Trials, Phase III as Topic, Oncology, Humans, Benzimidazoles, ORIGINAL REPORTS, Thyroid Neoplasms, Mitogen-Activated Protein Kinases, Protein Kinase Inhibitors
Abstract

PURPOSE Selumetinib can increase radioactive iodine (RAI) avidity in RAI-refractory tumors. We investigated whether selumetinib plus adjuvant RAI improves complete remission (CR) rates in patients with differentiated thyroid cancer (DTC) at high risk of primary treatment failure versus RAI alone. METHODS ASTRA (ClinicalTrials.gov identifier: NCT01843062 ) is an international, phase III, randomized, placebo-controlled, double-blind trial. Patients with DTC at high risk of primary treatment failure (primary tumor > 4 cm; gross extrathyroidal extension outside the thyroid gland [T4 disease]; or N1a/N1b disease with ≥ 1 metastatic lymph node(s) ≥ 1 cm or ≥ 5 lymph nodes [any size]) were randomly assigned 2:1 to selumetinib 75 mg orally twice daily or placebo for approximately 5 weeks (no stratification). On treatment days 29-31, recombinant human thyroid-stimulating hormone (0.9 mg)–stimulated RAI (131I; 100 mCi/3.7 GBq) was administered, followed by 5 days of selumetinib/placebo. The primary end point (CR rate 18 months after RAI) was assessed in the intention-to-treat population. RESULTS Four hundred patients were enrolled (August 27, 2013-March 23, 2016) and 233 randomly assigned (selumetinib, n = 155 [67%]; placebo, n = 78 [33%]). No statistically significant difference in CR rate 18 months after RAI was observed (selumetinib n = 62 [40%]; placebo n = 30 [38%]; odds ratio 1.07 [95% CI, 0.61 to 1.87]; P = .8205). Treatment-related grade ≥ 3 adverse events were reported in 25/154 patients (16%) with selumetinib and none with placebo. The most common adverse event with selumetinib was dermatitis acneiform (n = 11 [7%]). No treatment-related deaths were reported. CONCLUSION Postoperative pathologic risk stratification identified patients with DTC at high risk of primary treatment failure, although the addition of selumetinib to adjuvant RAI failed to improve the CR rate for these patients. Future strategies should focus on tumor genotype–tailored drug selection and maintaining drug dosing to optimize RAI efficacy.

Published
2022
Full Text
View/download PDF

24. An Undetectable Postoperative Calcitonin Level Is Associated with Long-Term Disease-Free Survival in Medullary Thyroid Carcinoma: Results of a Retrospective Cohort Study

Author

Duval, Marta Amaro da Silveira, primary, Ferreira, Carla Vaz, additional, Marmitt, Laura, additional, Dora, José Miguel, additional, Espíndola, Mateus, additional, Benini, Antonio Felipe, additional, Camelier, Marli Viapiana, additional, Bulzico, Daniel, additional, Andrade, Fernanda Accioly de, additional, Alves Júnior, Paulo Alonso, additional, Corbo, Rossana, additional, Vaisman, Fernanda, additional, Zanella, André Borsatto, additional, Scheffel, Rafael Selbach, additional, and Maia, Ana Luiza, additional

Published
2023
Full Text
View/download PDF

25. Guidelines from the Brazilian society of surgical oncology regarding indications and technical aspects of neck dissection in papillary, follicular, and medullary thyroid cancers

Author

Farias, Terence, primary, Kowalski, Luiz Paulo, additional, Dias, Fernando, additional, Barreira, Carlos S. Ritta, additional, Vartanian, José Guilherme, additional, Tavares, Marcos Roberto, additional, Vaisman, Fernanda, additional, Momesso, Denise, additional, Oliveira, Alexandre Ferreira, additional, Pinheiro, Rodrigo Nascimento, additional, and Ribeiro, Heber Salvador de Castro, additional

Published
2023
Full Text
View/download PDF

26. Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial

Author

Brose, Marcia S., primary, Robinson, Bruce G., additional, Sherman, Steven I., additional, Jarzab, Barbara, additional, Lin, Chia‐Chi, additional, Vaisman, Fernanda, additional, Hoff, Ana O., additional, Hitre, Erika, additional, Bowles, Daniel W., additional, Sen, Suvajit, additional, Oliver, Jennifer W., additional, Banerjee, Kamalika, additional, Keam, Bhumsuk, additional, and Capdevila, Jaume, additional

Published
2022
Full Text
View/download PDF

27. Guia Prático em Doenças da Tireoide

Author

Marchi Júnior, Adriano Francisco De, primary, Cury, Adriano Namo, additional, Moraes, Aline Barbosa, additional, Maia, Ana Luiza, additional, Hoff, Ana O., additional, Zanella, André Borsatto, additional, Sousa, Bárbara Érika Caldeira Araújo, additional, Fonseca, Bernardo Lopes Cançado, additional, Ferraz, Carolina, additional, Nascimento, Caroline Serrano do, additional, Nogueira, Célia Regina, additional, Camacho, Cleber P., additional, Mesa Junior, Cleo Otaviano, additional, Villagelin Neto, Danilo Glauco Pereira, additional, Moroto, Débora, additional, Momesso, Denise, additional, Bandeira, Diego, additional, Kimura, Edna Teruko, additional, Ferreira, Eduardo Henrique Rodrigues, additional, Tomimori, Eduardo Kiyoshi, additional, Farias, Evelin Cavalcante, additional, Miasaki, Fabíola Yukiko, additional, Bolfi, Fernanda, additional, Junqueira, Fernanda Damasceno, additional, Faro, Fernanda Nascimento, additional, Vaisman, Fernanda, additional, Coura Filho, George Barberio, additional, Vieira, Gil Kruppa, additional, Carvalho, Gisah Amaral de, additional, Mazeto, Gláucia Maria Ferreira da Silva, additional, Penna, Gustavo Cancela e, additional, Paula, Gustavo Ivani de, additional, Graf, Hans, additional, Ramos, Helton Estrela, additional, Barreto, Icléia Siqueira, additional, Pansani, Isabella Fagian, additional, Leão, Isabella Sued, additional, Cerutti, Janete, additional, Machado, Jéssica Cisotto, additional, Martins, João Roberto Maciel, additional, Sgarbi, José Augusto, additional, Dora, José Miguel, additional, Vidart, Josi, additional, Costa, Julia Magarão, additional, Velloni, Julia Maranhão Fagundes, additional, Rajão, Kamilla Maria Araújo Brandão, additional, Manosso, Karina Zanlorenzi Basso, additional, Campos, Larissa, additional, Marmitt, Laura, additional, Ward, Laura Sterian, additional, Hyppolito, Leandro Tinagero, additional, Maciel, Léa Maria Zanini, additional, Gastapaglia, Leila, additional, Walter, Leonardo Barbi, additional, Vieira Neto, Leonardo, additional, Cunha, Lucas Leite, additional, Souza, Luciana SantAna Leone de, additional, Oliveira, Luciana Souza de, additional, Cardoso, Ludmilla Ferreira, additional, Sisdelli, Luiza, additional, Cohen, Marcela Vaisberg, additional, Souza, Marcelo Cruzick de, additional, Cordioli, Maria Isabel Vieira, additional, Chiamolera, Maria Izabel, additional, Nunes, Maria Tereza, additional, Oliveira, Mariana Mazeu Barbosa de, additional, Iessi, Mariana Riello Gomes, additional, Vaisman, Mario, additional, Cançado, Natália Amaral, additional, Treistman, Natália, additional, Búfalo, Natássia Elena, additional, Morais, Nathalie Silva de, additional, Alkmim, Nina Ramalho, additional, Teixeira, Patrícia de Fátima dos Santos, additional, Magalhães, Patrícia Kunzle Ribeiro, additional, Marschner, Rafael Aguiar, additional, Scheffel, Rafael Selbach, additional, Campos, Renata de Oliveira, additional, Delfim, Ricardo Luiz Costantin, additional, Biscolla, Rosa Paula Mello, additional, Padovani, Rosália do Prado, additional, Camargo, Rosalinda Yossie Asato de, additional, Pfeilsticker, Rudolf Moreira, additional, Maciel, Rui Monteiro de Barros, additional, Anunciação, Sara Moreira, additional, and Wajner, Simone, additional

Published
2022
Full Text
View/download PDF

30. Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-Targeted yherapy: updated results from the phase 3 COSMIC-311 trial and prespecified subgroup analyses based on prior therapy

Author

Durante, Cosimo, primary, Brose, Marcia, additional, Robinson, Bruce, additional, Sherman, Steven I, additional, Jarzab, Barbara, additional, Lin, Chia-Chi, additional, Vaisman, Fernanda, additional, Hoff, Ana O, additional, Hitre, Erika, additional, Bowles, Daniel W, additional, Sen, Suvajit, additional, Patel, Purvi, additional, Keam, Bhumsuk, additional, and Capdevila, Jaume, additional

Published
2022
Full Text
View/download PDF

31. Effect of age on efficacy and safety of cabozantinib vs placebo in patients with radioiodine refractory (RAI-R)-differentiated thyroid cancer (DTC) with progression after VEGFR-targeted therapy: subgroup analysis from Phase 3 COSMIC 311 study

Author

Durante, Cosimo, primary, Robinson, Bruce, additional, Sherman, Steven I, additional, Krajewska, Jolanta, additional, Lin, Chia-Chi, additional, Vaisman, Fernanda, additional, Hoff, Ana O, additional, Hitre, Erika, additional, Bowles, Daniel W, additional, Hernando, Jorge, additional, Banerjee, Kamalika, additional, Levytskyy, Roman M, additional, Oliver, Jennifer W, additional, Keam, Bhumsuk, additional, Capdevila, Jaume, additional, and Brose, Marcia, additional

Published
2022
Full Text
View/download PDF

32. Puberty and sex in pediatric thyroid cancer: could expression of estrogen and progesterone receptors affect prognosis?

Author

da Silva Breder, Julia Ramalho Amalio, primary, Alves, Paulo Alonso Garcia, additional, Araújo, Mario Lucio, additional, Pires, Barbara, additional, Valverde, Priscila, additional, Bulzico, Daniel Alves, additional, Accioly, Fernanda Andrade, additional, Corbo, Rossana, additional, Vaisman, Mario, additional, and Vaisman, Fernanda, additional

Published
2022
Full Text
View/download PDF

34. An Undetectable Postoperative Calcitonin Level Is Associated with Long-Term Disease-Free Survival in Medullary Thyroid Carcinoma: Results of a Retrospective Cohort Study.

Author

da Silveira Duva, Marta Amaro, Vaz Ferreira, Carla, Marmitt, Laura, Miguel Dora, José, Espíndola, Mateus, Felipe Benini, Antonio, Viapiana Camelier, Marli, Bulzico, Daniel, Accioly de Andrade, Fernanda, Alves Júnior, Paulo Alonso, Corbo, Rossana, Vaisman, Fernanda, Borsatto Zanella, André, Selbach Scheffel, Rafael, and Luiza Maia, Ana

Published
2023
Full Text
View/download PDF

36. Clinical Outcomes After Radioiodine Therapy, According to the Method of Preparation by Recombinant TSH vs. Endogenous Hypothyroidism, in Thyroid Cancer Patients at Intermediate-High Risk of Recurrence

Author

Higuchi, Cynara Rena Salmont, primary, Fernanda, Paula, additional, Jurnior, Paulo Alonso, additional, Andrade, Fernanda Accioly, additional, Corbo, Rossana, additional, Vaisman, Mario, additional, Vaisman, Fernanda, additional, and Bulzico, Daniel, additional

Published
2021
Full Text
View/download PDF

39. Cholestatic syndrome as initial manifestation of pancreatic metastasis of papillary thyroid carcinoma: case report and review

Author

Tramontin,Mariana Yoshii, Faria,Paulo Antônio Silvestre de, Nascimento,Cristina Moreira do, Barbosa,Cibele de Aquino, Barros,Maria de Fátima Rei Pereira, Barros,Aniela Rodrigues Gomes de, Carvalho,Rafaela Cardoso de, Castro Neto,Antônio Kneipp Pitta de, Andrade,Fernanda Accioly de, Corbo,Rossana, Vaisman,Fernanda, and Bulzico,Daniel

Subjects
endocrine system diseases
Abstract

SUMMARY Most papillary thyroid carcinomas (PTC) harbor excellent prognosis. Although rare, distant metastases normally occur in lungs and/or bones. Here we describe a rare case of pancreatic metastasis presenting with rapid onset cholestatic syndrome. A literature review was also performed. A 73-year-old man with a high risk PTC was submitted to total thyroidectomy (TT) followed by radioiodine therapy. After initial therapy, he persisted with progressive rising serum thyroglobulin levels but with no evidence of structural disease. Recently, the patient presented with a rapid onset and progressive cholestatic syndrome. A 4 cm lesion in pancreas was identified, with echoendoscopy fine-needle aspiration biopsy (FNAB) confirming a pancreatic metastasis from PTC. The patient was submitted to a successful pancreaticoduodenectomy. Pancreatic metastases of PTC are rare and few long-term follow-up data are available to guide management. Fourteen cases were former reported, mean age was 65.7 years-old with mean time between PTC and pancreatic metastasis diagnosis of 7.9 years. Nine of them had another distant metastasis, nine were diagnosed by FNAB and just two received sorafenib.

Published
2020

40. Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial.

Author

Brose, Marcia S., primary, Robinson, Bruce, additional, Sherman, Steven I., additional, Jarzab, Barbara, additional, Lin, Chia-Chi, additional, Vaisman, Fernanda, additional, Hoff, Ana, additional, Hitre, Erika, additional, Bowles, Daniel W., additional, Faoro, Leonardo, additional, Banerjee, Kamalika, additional, Oliver, Jennifer, additional, Keam, Bhumsuk, additional, and Capdevila, Jaume, additional

Published
2021
Full Text
View/download PDF

41. Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors – a single Brazilian center experience

Author

Treistman, Natalia, primary, Nobre, Gabriela Maia, additional, Tramontin, Mariana Yoshii, additional, Silva, Gabriel Madeira Werberich da, additional, Herchenhorn, Daniel, additional, Araujo, Luiz Henrique de Lima, additional, Andrade, Fernanda Accioly de, additional, Corbo, Rossana, additional, Bulzico, Daniel, additional, and Vaisman, Fernanda, additional

Published
2021
Full Text
View/download PDF

45. Choosing Wisely for Thyroid Conditions: Recommendations of the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism

Author

Dora, Jose Miguel, primary, Biscolla, Rosa Paula Mello, additional, Caldas, Gustavo, additional, Cerutti, Janete, additional, Graf, Hans, additional, Hoff, Ana O., additional, Mazeto, Glaucia M. F. S., additional, Magalhães, Patrícia Kunzle Ribeiro, additional, Mesa, Cleo Otaviano, additional, Scheffel, Rafael Selbach, additional, Teixeira, Patricia de Fatima dos Santos, additional, Vaisman, Fernanda, additional, Villagelin, Danilo, additional, and Maia, Ana Luiza, additional

Published
2021
Full Text
View/download PDF

46. A Multifocal Pediatric Papillary Thyroid Carcinoma (PTC) Harboring the AGK-BRAF and RET/PTC3 Fusion in a Mutually Exclusive Pattern Reveals Distinct Levels of Genomic Instability and Nuclear Organization

Author

Sisdelli, Luiza, primary, Cordioli, Maria Isabel V., additional, Vaisman, Fernanda, additional, Monte, Osmar, additional, Longui, Carlos A., additional, Cury, Adriano N., additional, Freitas, Monique O., additional, Rangel-Pozzo, Aline, additional, Mai, Sabine, additional, and Cerutti, Janete M., additional

Published
2021
Full Text
View/download PDF

47. Real-world, Prospective, and Multicenter Validation of a microRNA-based Thyroid Molecular Classifier

Author

dos Santos, Marcos Tadeu, primary, Rodrigues, Bruna Moretto, additional, Shizukuda, Satye, additional, Alves Figueiredo, David Livingstone, additional, de Melo, Giulianno Molina, additional, da Silva, Rubens Adão, additional, Fainstein, Claudio, additional, dos Reis, Gerson Felisbino, additional, Corbo, Rossana, additional, Ramos, Helton Estrela, additional, Vaisman, Fernanda, additional, and Vaisman, Mário, additional

Published
2020
Full Text
View/download PDF

50. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey

Author

Reiners, Christoph, primary, Schneider, Rita, additional, Platonova, Tamara, additional, Fridman, Mikhail, additional, Malzahn, Uwe, additional, Mäder, Uwe, additional, Vrachimis, Alexis, additional, Bogdanova, Tatiana, additional, Krajewska, Jolanta, additional, Elisei, Rossella, additional, Vaisman, Fernanda, additional, Mihailovic, Jasna, additional, Costa, Gracinda, additional, and Drozd, Valentina, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results